Cystatin C antagonizes transforming growth factor β signaling in normal and cancer cells

Molecular Cancer Research

Volumn 2, Issue 3, 2004, Pages 183-195

  Sokol, Jonathan P ^a   Schiemann, William P ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYSTATIN C; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN 3T3; FEEDBACK SYSTEM; FIBROBLAST; FIBROSARCOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ANIMALS; CATHEPSINS; CELL LINE, TUMOR; CYSTATINS; GENE DELETION; GENE EXPRESSION REGULATION; GENES, REPORTER; GENETIC VECTORS; HUMANS; MICE; NEOPLASM INVASIVENESS; PROTEIN BINDING; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE;

EID: 3543106256     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Vray B, Hartmann S, Hoebeke J. Immunomodulatory properties of cystatins. Cell Mol Life Sci, 2002;59:1503-12.
2. Brown WM, Dziegielewska KM. Friends and relations of the cystatin superfamily-new members and their evolution. Protein Sci, 1997;6:5-12.
3. Kos J, Werle B, Lah T, Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers, 2000;15:84-9.
4. Turk V, Turk B, Guncar G, Turk D, Kos J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul, 2002;42:285-303.
5. Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem, 2003;384:845-54.
6. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta, 2000;1477:98-111.
7. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev, 2003;22:271-86.
8. Bode W, Engh R, Musil D, et al. The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J, 1988;7:2593-9.
9. Stubbs MT, Laber B, Bode W, et al. The refined 2.4 A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 1990;9:1939-47.
10. Nycander M, Estrada S, Mort JS, Abrahamson M, Bjork I. Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop. FEBS Lett, 1998;422:61-4.
11. Sun Q. Growth stimulation of 3T3 fibroblasts by cystatin. Exp Cell Res, 1989;180:150-60.
12. Tavera C, Leung-Tack J, Prevot D, et al. Cystatin C secretion by rat glomerular mesangial cells: autocrine loop for in vitro growth-promoting activity. Biochem Biophys Res Commun, 1992;182:1082-8.
13. Olafsson I, Thorsteinsson L, Jensson O. The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Brain Pathol, 1996;6:121-6.
14. Dworkin LD. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens, 2001;10:551-3.
15. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem, 2002;48:699-707.
16. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res, 2000;6:505-11.
17. Kos J, Stabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem, 1998;44:2556-7.
18. Zore I, Krasovec M, Cimerman N, et al. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem, 2001;382:805-10.
19. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med, 2000;342:1350-8.
20. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell, 2000;103:295-309.
21. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet, 2001;29:117-29.
22. Solem M, Rawson C, Lindburg K, Barnes D. Transforming growth factor β regulates cystatin C in serum-free mouse embryo (SFME) cells. Biochem Biophys Res Commun, 1990;172:945-51.
23. Afonso S, Tovar C, Romagnano L, Babiarz B. Control and expression of cystatin C by mouse decidual cultures. Mol Reprod Dev, 2002;61:155-63.
24. Shi GP, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest, 1999;104:1191-7.
25. Kothapalli R, Bailey RD, Kusmartseva I, Mane S, Epling-Burnette PK, Loughran TP Jr. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol, 2003;22:33-9.
26. Korolenko TA, Poteryaeva ON, Falameeva OV, Levina OA. Cystein proteinase inhibitor stefin A as an indicator of efficiency of tumor treatment in mice. Bull Exp Biol Med, 2003;136:46-8.
27. Korolenko TA, Poteryaeva ON, Djanayeva SJ, ct al. Cystatin C in LS lymphosarcoma and HA-1 hepatoma treated with Ukrain and cyclophosphamide and involvement of apoptosis. Drugs Exp Clin Res, 2000;26:285-92.
28. Usova TA, Poteryaeva ON, Zhanayeva SY, Yarygina ES, Korolenko TA. Cystatin C and cysteine proteinases during the development and therapy of Lewis lung adenocarcinoma in mice. Bull Exp Biol Med, 2003;135:81-4.
29. Calkins CC, Sameni M, Koblinski J, Sloane BF, Moin K. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy. J Histochem Cytochem, 1998;46:745-51.
30. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M, Sloane BF. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate, 1995;26:171-8.
31. Sameni M, Moin K, Sloane BF. Imaging proteolysis by living human breast cancer cells. Neoplasia, 2000;2:496-504.
32. Mai J, Waisman DM, Sloane BF. Cell surface complex of cathepsin B/ annexin 11 tetramer in malignant progression. Biochim Biophys Acta, 2000;1477:215-30.
33. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res, 2001;61:3493-500.
34. Premzl A, Zavasnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res, 2003;283:206-14.
35. Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D, Sordat B. Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer, 1992;52:645-52.
36. Hua X, Liu X, Ansari DO, Lodish HF. Synergistic cooperation of TFE3 and Smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev, 1998;12:3084-95.
37. Auerswald EA, Genenger G, Assfalg-Machleidt I, Machleidt W, Engh RA, Fritz H. Recombinant chicken egg white cystatin variants of the QLVSG region. Eur J Biochem, 1992;209:837-45.
38. Auerswald EA, Nagler DK, Assfalg-Machleidt 1, Stubbs MT, Machleidt W, Fritz H. Hairpin loop mutations of chicken cystatin have different effects on the inhibition of cathepsin B, cathepsin L and papain. FEBS Lett, 1995;361:179-84.
39. Sexton PS, Cox JL. Inhibition of motility and invasion of B16 melanoma by the overexpression of cystatin C. Melanoma Res, 1997;7:97-101.
40. Somanna A, Mundodi V, Gedamu L. Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor β. J Biol Chem, 2002;277:25305-12.
41. Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ Jr. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-βL a process initiated by the exocytosis of cathepsin B. J Biol Chem, 2002;277:14829-37.
42. Gantt KR, Schultz-Cherry S, Rodriguez N, et al. Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol, 2003;170:2613-20.
43. Wrana JL, Attisano L, Carcamo J, et al. TGF β signals through a heteromeric protein kinase receptor complex. Cell, 1992;71:1003-14.
44. Szweras M, Liu D, Partridge EA, et al. α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem, 2002;277:19991-7.
45. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem, 1999;274:28514-20.
46. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/ α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem, 1996;271:12755-61.
47. Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol, 2000;1:169-78.
48. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands. J Biol Chem, 1995;270:2747-54.
49. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res, 2001;7:2931-40.
50. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res, 1999;84:1212-22.
51. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res, 1999;59:1273-7.
52. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature, 2001;411:375-9.
53. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res, 2001;264:169-84.
54. Konduri SD, Yanamandra N, Siddique K, et al, Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene, 2002;21:8705-12.
55. Coulibaly S, Schwihla H, Abrahamson M, et al. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int J Cancer. 1999;83:526-31.
56. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop, 2003;415:S46-58.
57. Cavallo-Medved D, Sloane BF. Cell-surface cathepsin B: understanding its functional significance. Curr Top Dev Biol, 2003;54:313-41.
58. Wakefield LM, Piek E, Bottinger EP. TGF-β signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia, 2001;6:67-82.
59. Kos J, Stabuc B, Schweiger A, et al. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res, 1997;3:1815-22.
60. Huh CG, Hakansson K, Nathanson CM, et al. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol, 1999;52:332-40.
61. Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion: Fibulin-5 is induced by TGF-β and affects protein kinase cascades. J Biol Chem, 2002;277:27367-77.
62. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-β-signaling system. Mol Biol Cell, 2003;14:3977-88.
63. Schiemann WP, Graves LM, Baumann H, et al. Phosphorylation of the human leukemia inhibitory factor (LIF) receptor by mitogen-activated protein kinase and the regulation of LIF receptor function by heterotogous receptor activation. Proc Natl Acad Sci USA, 1995;92:5361-5.
64. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood, 1999;94:2854-61.